Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-17
1997-02-25
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514844, 514864, A61K 3135
Patent
active
056059272
ABSTRACT:
The invention refers to the treatment and prevention of lyso paf-mediated skin disorders with an effective amount of at least one antagonists against lyso paf receptors. Lyso paf or paf receptor antagonists were administered with or without an antagonist against production of ether phospholipids. Lyso paf antagonists are Ginkgoloides which are administered, for example, by food or topically.
REFERENCES:
patent: 4571407 (1986-02-01), Chatterjee et al.
patent: 4595693 (1986-06-01), Biftu et al.
patent: 4734280 (1988-03-01), Braquet
patent: 5147864 (1992-09-01), Wissner et al.
patent: 5202313 (1993-04-01), Bombardelli et al.
patent: 5334592 (1994-08-01), Billah
Meade et al., Biochem. Pharm, vol. 41, No. 5 (1991) 657-668, "Biochemical Pharmacology of Platelet-Activating Factor (and Paf Antagonists) in Relation to Clinical and Experimental Thrombocytopenia".
Goldman et al., New Engl. J. Med., vol. 318, No. 7, (1990) 397-403 "Mechanisms of Altered Water Metabolism in Psychotic Patients with Polydipsia and Hyponatremia".
Yue et al., Am. Soc. Pharmacol. and Exp. Ther., vol. 257 (1991) 374-381 "Platelet-Activating Factor (PAF) Receptor-Mediated Calcium Mobilization and Phosphoinositude Turnover in Neurohybrid NG108-15 Cells: Studies with BN50739, a New PAF Antagonist".
Pfeilschifter et al., Eur. J. Biochem, 181 (1989) 237-242, "Release of phospholipase A.sub.2 activity from rat vascular smooth muscle cells mediated by cAMP".
Tetta et al., J. Pharmacol. and Exp. Ther., vol. 257 (1990) 616-620 "Inhibition of the Synthesis of Platelet-Activating Factor by Anti-Inflammatory Peptides (Antiflammins) Without Methionine".
Lekka et al., Biochimica et Biophysica Acta, 1042 (1990) 217-220, "In vivo metabolism of platelet-activating-factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by the protozoan Tetrahymena pyriformis".
Benveniste et al., J. of Exp. Med., 136 (1972) 1356-1377, "Leukocyte-Dependent Histamine Release from Rabbit Platelets".
Korth et al., Eur. J. Pharmacology, 152 (1988) 101-110, "Comparison of three paf-acether receptor antagonist ginkgolides".
Korth et al., Br. J. Pharmacol., 98 (1989) 653-661, "Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells".
Malech et al., New Engl. J. Med., vol. 317, No. 11, (1987) 687-694 "Current Concepts: Immunology--Neutrophils in Human Diseases".
Sperling et al., J. Immunol., 139 (1987) 4186-4191, "The Effects of N-3 Polyunsaturated Fatty Acids on the Generation of Platelet-Activating Factor-Acether by Human Monocytes".
Llorens-Cortes et al., J. Biological Chem., 267 (1992) 14012-14018 "Identification and Characterization of Neural Endopeptidase in Endothelial Cells from Venous or Arterial Origins".
Benveniste et al., C. R. Acad. Sc. Paris, 289 (1979) 1037-1377 "Semi-synth ese et structure propos ee du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine".
Korth et al., Lipids, vol. 28, No. 3 (1993) 193-199, "Human Platelets Release a Paf-Acether: Acetylhydrolase Similar to That in Plasma".
Honda et al., Nature, vol. 349 (1991) 342-346), "Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung".
Criares Theodore J.
Korth Ruth
LandOfFree
Treatment of skin diseases using ginkgolide PAF antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of skin diseases using ginkgolide PAF antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of skin diseases using ginkgolide PAF antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1974317